Aurora Cannabis has no U.S. dispensaries, no American cultivation licenses, and no plant-touching assets on American soil. Yet CEO Miguel Martin is watching the federal rescheduling process as closely as any domestic operator - because he believes a Schedule 3 designation could open a path into the U.S. medical market without requiring Aurora to own a single American facility. That read on the regulatory moment is worth paying attention to, particularly as the DEA's administrative hearing on moving adult-use cannabis from Schedule 1 to Schedule 3 continues to grind forward.
The strategic logic here matters to more than just Aurora's investors. For U.S. operators - whether a single-state dispensary group tracking wholesale competition or a multi-state operator thinking about licensing and supply chain exposure - the arrival of well-capitalized international licensed producers into the American medical market would reshape wholesale pricing, product standards, and compliance expectations. Operators in tightly regulated states already running sophisticated POS software for New Jersey cannabis retailers and similar systems understand how much regulatory architecture shapes competitive dynamics; federal rescheduling could add a new layer of that complexity, particularly if it opens the door to foreign GMP-certified producers.
Aurora reported $48.8 million in international medical cannabis revenue for the three months ended March 31. For the full fiscal year ended on that date, international medical revenue increased by $39.5 million, driven primarily by stronger sales in Germany. The company operates medical cannabis businesses across 12 countries and has built its model around good manufacturing practices - the pharmaceutical-grade production standards that European regulators, particularly in Germany and Poland, require for legal medical cannabis. That's not a marketing claim. GMP certification involves documented manufacturing processes, independent audits, and the kind of product traceability infrastructure that U.S. regulators would likely require if FDA takes a central oversight role post-rescheduling.
The Partnership Model - And Why 280E Isn't the Point
Most of the domestic conversation around Schedule 3 has centered on Section 280E of the Internal Revenue Code - the provision that bars plant-touching cannabis businesses from deducting ordinary business expenses, effectively imposing a much higher effective tax rate than non-cannabis companies face. For American operators sitting on thin margins after years of oversupply, price compression, and high state excise taxes, 280E relief would be significant. Martin's position is different. He's less interested in the tax structure and more focused on whether a Nasdaq-listed Canadian company could participate in a U.S. medical market through a partnership arrangement - one that doesn't require Aurora to consolidate U.S. assets onto its balance sheet.
"Whether you partner but not consolidate it … is the big question," Martin told MJBizDaily. That framing matters because it suggests a licensing or distribution model rather than equity ownership - the kind of structure that could allow a foreign producer to supply product or intellectual property into the U.S. market without triggering the plant-touching restrictions that currently make U.S. cannabis stocks ineligible for major exchanges. The mechanics of that structure would depend entirely on how federal agencies write the rules once rescheduling takes effect - which is precisely why Martin is focused on which agency leads: FDA, DEA, or some combination.
The FDA Question and a GMP Advantage
Martin points to the roughly $7.2 billion acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals - built on the Epidiolex franchise, a cannabidiol-based drug that cleared a full FDA approval process - as evidence that cannabinoids can move through rigorous federal registration. If FDA takes a central role in regulating medical cannabis post-rescheduling, the compliance bar would likely resemble pharmaceutical drug oversight more than state-level dispensary licensing. That's a different competitive environment than the one most U.S. operators know.
Here's the catch for domestic players: most American cannabis businesses were built around state-level compliance frameworks - METRC integration, seed-to-sale tracking, state-specific testing protocols, and retail licensing rules that vary county by county. GMP manufacturing, pharmaceutical-grade documentation, and FDA-style registration are a different discipline entirely. Aurora has operated under those standards for years in markets like Germany and Poland, where pharmaceutical regulators run audits and product registration is mandatory. A U.S. medical market structured around FDA oversight would, in effect, reward companies that already know how to operate that way.
The Germany Workaround and What It Signals
Aurora operates a GMP production facility in Germany, and Martin has been explicit about one scenario: if direct Canada-to-U.S. cannabis shipments aren't permitted under the new federal framework, product could move from Germany to the U.S. instead. "If the U.S. exports to Germany, Germany could export to the U.S.," he said. That's a supply chain workaround built on Aurora's existing international infrastructure - and it signals how seriously the company is thinking through the operational constraints, not just the regulatory opportunity.
Martin also favors the European prescription model as a template for how U.S. medical cannabis could be structured: a physician's order, dispensed through a pharmacy, with specific product registration. He contrasted that with broader allowances that don't involve physician oversight of dosage and format. Whether U.S. regulators move toward that kind of framework - or settle for something closer to the current state-licensed dispensary model with a federal overlay - remains genuinely open. Martin doesn't expect the U.S. to impose standards stricter than Germany or Poland. That may well be right. But the direction of travel, if FDA is involved, is toward more documentation, more product registration, and more manufacturing accountability - not less.
For U.S. operators, the rescheduling story has mostly been about 280E and banking access. Those are real and immediate concerns. But the longer-term question - who gets to compete in an American medical cannabis market once it has a functional federal regulatory structure - is one that companies like Aurora are already positioning to answer.
